ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
update
/
details

Proscia Launches Concentriq® Embeddings and AI Toolkit to Accelerate AI-Driven Pathology and Medical Breakthroughs

NextEdge Admin

03 Oct 2024

2 min 26 sec

AI Toolkit,biomarker discovery,Pathology

Proscia®, a leader in AI-powered pathology solutions, has launched Concentriq® Embeddings and the Proscia AI Toolkit to speed up the discovery of new therapies and diagnostics. Integrated into the Concentriq platform, these tools provide pathology and data science teams with advanced models like DINOv2, PLIP, ConvNext, and CTransPath to generate high-dimensional embeddings from whole slide images. This enables rapid prototyping and large-scale AI model development for tasks such as image classification, biomarker discovery, and risk scoring.

The seamless integration of Concentriq Embeddings with existing data infrastructure eliminates the need for data migration or external processing, allowing researchers to instantly access pathology data and significantly cut development time. This streamlines AI experimentation, helping organizations accelerate the creation of clinically viable models. In a recent pilot program, researchers developed AI-based breast cancer biomarker prediction models 13 times faster, reducing the development timeline from weeks to hours.

Proscia’s AI Toolkit complements Concentriq Embeddings, offering open-source resources like a Python client, tutorials, and helper functions to support AI model building and deployment. This toolkit fosters collaboration within the life sciences community, enabling developers to share innovations and expand the toolkit with new techniques.

By accelerating AI adoption and innovation in digital pathology, Proscia’s Concentriq Embeddings and AI Toolkit empower researchers to achieve breakthroughs faster, paving the way for transformative advancements in both medical research and patient care. Proscia aims to drive a new era where AI enables faster, more accurate diagnostics and treatment development, potentially reaching patients worldwide.